Days after saying it would not distribute abortion pills in some states where the medication is legal, Walgreens appeared to revise its messaging on Monday evening. 

In February, Republican attorneys general in 20 states wrote to Walgreens and CVS, indicating legal action if the companies mailed abortion pills in their jurisdictions. 

Last week, Walgreens told Politico it responded to the aforementioned officials, confirming it would not dispense abortion pills by mail or at its brick-and-mortar stores in any of their states. 

Walgreens’ statement on Monday appeared to tweak its stance, promising to provide abortion medication in all states where it’s legal. 

“We want to be very clear about what our position has always been: Walgreens plans to dispense Mifepristone in any jurisdiction where it is legally permissible to do so,” the company said. 

Mifepristone is an oral abortion medication that blocks the hormone needed for a pregnancy to continue. In January, the Food and Drug Administration allowed certified pharmacies to dispense the drug to people who have a prescription. Walgreens and CVS quickly made clear their intention to sell the medication. 

Walgreens added in its statement that, once it is certified by the FDA, it will dispense mifepristone “consistent with federal and state laws.”

“Providing legally approved medications to patients is what pharmacies do, and is rooted in our commitment to the communities in which we operate,” the statement concluded. 

A Walgreens representative could not be immediately reached for further comment. 

The pharmacy store chain’s recent moves have already had ripple effects. California Governor Gavin Newsom said Monday afternoon that the state will officially cut ties with Walgreens.

Walgreens Boots Alliance reported sales of $33.4 billion in its fiscal Q1 2023, which ended November 30, a 1.5% decrease from the year-ago quarter. Net loss in Q1 was $3.7 billion, compared to net income of $3.6 billion in the same period last year. 

This article originally appeared on PRWeek US.